Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 23;5(2):dlad033.
doi: 10.1093/jacamr/dlad033. eCollection 2023 Apr.

Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin

Nicolás Merchante  1 , Rocío Herrero  1 , María Dolores Valverde-Fredet  1 , Miguel Rodríguez-Fernández  1 , Héctor Pinagorte  2 , Francisco J Martínez-Marcos  3 , Concepción Gil-Anguita  4 , María García-López  5 , María Tasias Pitarch  6 , Vicente Abril López De Medrano  7 , Miguel Nicolás Navarrete Lorite  8 , Cristina Gómez-Ayerbe  9   10 , Eva León  1 , Pilar González-De La Aleja  2 , Ana Ruiz Castillo  11 , Ana I Aller  1 , Juan Carlos Rodríguez  12 , Julia Ternero Fonseca  13 , Juan E Corzo  1 , Alberto Naranjo Pérez  13 , Marta Trigo-Rodríguez  1 , Esperanza Merino  2
Affiliations

Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin

Nicolás Merchante et al. JAC Antimicrob Resist. .

Erratum in

Abstract

Objectives: To investigate the role of previous antibiotic therapy in the risk of recurrence after a Clostridioides difficile infection (CDI) treated with vancomycin.

Methods: Multicentre observational study. Patients with a CDI episode achieving clinical cure with oral vancomycin and followed up 8 weeks were included. Previous antibiotic exposure up to 90 days was collected. Multivariate analysis of predictors of recurrence adjusted by the propensity score (PS) of being previously treated with each non-CDI antibiotic was performed.

Results: Two hundred and forty-one patients were included; 216 (90%) had received systemic antibiotics. Fifty-three patients (22%) had a CDI recurrence. Rates of recurrence were lower in those treated with piperacillin/tazobactam in the last month when compared with those not receiving piperacillin/tazobactam [3 (7%) versus 50 (25%); P = 0.01], whereas higher rates were seen in those treated with cephalosporins in the last month [26/87 (30%) versus 27/154 (17%); P = 0.03]. In multivariate analysis controlled by the inverse probability of treatment weighting by PS, receiving ≥5 days of piperacillin/tazobactam in the last month as the last antibiotic regimen prior to CDI was independently associated with a lower risk of recurrence [adjusted OR (AOR) 0.13; 95% CI: 0.06-0.29; P < 0.0001] whereas exposure for ≥5 days to cephalosporins (versus piperacillin/tazobactam) was associated with an increased risk (AOR 10.9; 95% CI: 4.4-27.1; P < 0.0001).

Conclusions: Recent use of piperacillin/tazobactam might be associated with a lower risk of CDI recurrence, while recent use of cephalosporins might promote an increased risk. These findings should be considered when treating hospitalized patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Risk of CDI recurrence according to previous exposure to systemic non-CDI antibiotics (ATB) (n = 244). TZP, piperacillin/tazobactam. (a) TZP. (b) Cephalosporins.
See this image and copyright information in PMC

References

    1. Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825–34. 10.1056/NEJMoa1408913 - DOI - PMC - PubMed
    1. Davies KA, Longshaw CM, Davis GL et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicenter, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalized patients with diarrhea (EUCLID). Lancet Infect Dis 2014; 14: 1208–19. 10.1016/S1473-3099(14)70991-0 - DOI - PubMed
    1. Longo DL, Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372: 1539–48. 10.1056/NEJMra1403772 - DOI - PubMed
    1. Stevens V, Dumyati G, Fine LS et al. Cumulative antibiotic exposure over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42–8. 10.1093/cid/cir301 - DOI - PubMed
    1. Kavanagh K, Pan J, Marwick C et al. Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case-control study using administrative data. J Antimicrob Chemother 2017; 72: 1193–201. 10.1093/jac/dkw528 - DOI - PubMed

LinkOut - more resources